MERCK SAYS INTISMERAN PLUS KEYTRUDA SIGNIFICANTLY REDUCED THE RISK OF RECURRENCE OR DEATH BY 42% COMPARED TO KEYTRUDA ALONE, WITH A 58% REDUCTION IN ANOTHER MEASURE, AND THAT THE SAFETY PROFILE WAS GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED STUDIES OF THE COMBINATION